DIAGNOSIS OF TAMOXIFEN SENSITIVITY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Jun 1, 2007
filing date -
Dec 3, 2004
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Data indicates that adjuvant tamoxifen treatment adversely influences outcome in breast cancer with CCND1-amplification and in fact severely promotes disease progress. The present invention thus relates to a method for diagnosing sensitivity to tamoxifen by monitoring the amplification of the gene for cyclin D1, CCND1.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully